Although the association between alpha 1-antitrypsin deficiency (α1ATD) carriers and lung cancer risk has been found, the effects of α1ATD carriers and serum alpha 1-antitrypsin (α1AT) concentration on non-small cell lung cancer (NSCLC) survival remained unclear. Methods: Patients were selected from the Epidemiology and Genetics of Lung Cancer Study at Mayo Clinic with the criteria of (1) primary NSCLC diagnosis and (2) available α1ATD carrier status tested by isoelectric focusing serum α1AT concentration by immunonephelometry. The effects of carrier status and serum α 1AT concentration on survival were evaluated by Cox proportional hazards models with (1) a landmark approach, where overall survival was defined from the time of blood draw to death from any cause and (2) included only patients with blood draw time before initial treatment. Results: One thousand three hundred twenty-one patients were included in this study, with 179 α1ATD carriers and 1142 noncarriers. No differences in overall survival by α1ATD carrier status were found (adjusted hazard ratio [AHR]: 0.98; 95% confidence interval [CI]: 0.82-1.18). Nevertheless, serum α1AT concentration was significantly associated with survival among all patients in the landmark model (AHR per 50 mg/dl increments: 1.15; 95% CI: 1.10-1.20) and among patients whose blood was drawn for serum α1AT level assessment before any treatment (AHR per 50 mg/dl increments: 1.44; 95% CI: 1.21-1.71). Conclusions: Being an α 1ATD carrier had no significant effect on NSCLC survival. The increased serum α1AT concentration was a poor prognosis marker for NSCLC, regardless of carrier status.
- Alpha 1-antitrypsin
- Alpha 1-antitrypsin deficiency
- Non-small cell lung cancer
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine